Ziekenhuizen enza/BI, projectcode 1280.8

Deelnemende ziekenhuizen aan de studie enza/BI, projectcode 1280.8.

The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate resistant prostate cancer (CRPC) patients that have previously been treated and failed on docetaxel and abiraterone treatments.

[table “15” not found /]

© 2018, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in